# Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia

> **NCT00485823** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 48 (actual)

## Conditions studied

- Schizophrenic Disorders

## Interventions

- **DRUG:** Olanzapine Hydrochloride
- **PROCEDURE:** Weight Management Program

## Key facts

- **NCT ID:** NCT00485823
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** —
- **Final completion:** 2003-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2007-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00485823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00485823, "Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00485823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*